Benign small bowel pneumatosis intestinalis: report of a rare adverse effect of tirzepatide Authors: Kenneth Newcomer, Hani Soudah, Michael Beal, Thoi H Ngo Published: 2025 What would you do? A patient in his 50s, with HTN, HLD, GERD, and obesity (class II, BMI 36 kg/m2), presented with abdominal pain and bloating. Notably, he does not have diabetes mellitus. He was receiving weekly tirzepatide subcutaneous injections for a medically supervised weight loss program. He tolerated these treatments with mild GI symptoms, and his dosage was up-titrated to 15 mg. Approximately 48 hours after the fourth dose of tizepatide 15 mg, the patient experienced abdominal cramps and distension. He sought evaluation at the ED 5 days afterward because his symptoms were more prolonged and severe compared with similar symptoms that he had experienced after prior doses. He did not experience any vomiting, jaundice, melena, or hematochezia. Initial evaluation revealed tenderness in the right upper quadrant and epigastrium without rebound, guarding, or rigidity. Laboratory tests were notable for white blood cell count 9.9 × 109/L, ALT 67 units/L, AST 34 units/L, and Lipase 25 units/L. Vital signs were reassuring and remained within expected limits. A CT scan of the abdomen and pelvis with intravenous contrast was obtained, which revealed gas within the wall of multiple loops of small bowel in the right upper quadrant, consistent with pneumatosis intestinalis, and multiple small locules of extraluminal gas in the small bowel mesentery, adjacent to the liver, and under the right hemidiaphragm (figure 1). There was no free fluid or inflammatory fat stranding. CT scan of the abdomen and pelvis (August 31, 2024): hospital day 0. Small bowel pneumatosis intestinalis, pneumoperitoneum. What would you do to manage benign pneumatosis intestinalis? Diagnostic laparoscopy. Diagnostic laparoscopy. Exploratory laparotomy. Exploratory laparotomy. Bowel rest, repeat CT scan of the abdomen and pelvis in 24–48 hours. Bowel rest, repeat CT scan of the abdomen and pelvis in 24–48 hours. Esophagogastroduodenoscopy. Esophagogastroduodenoscopy. What we did and why After multidisciplinary discussions among surgery, radiology, and endocrinology teams, this presentation was analyzed to be most consistent with benign pneumatosis intestinalis. Notably, symptoms were temporally associated with the initiation and titration of tirzepatide. Often, radiographic findings of pneumatosis intestinalis and pneumoperitoneum would indicate emergent operative intervention. However, the patient’s lack of peritonitis on examination, persistent hemodynamic stability, and normal biochemical work-up were not congruent with bowel ischemia or hollow viscus perforation. At this point, the clinical question was whether or not to pursue operative exploration. He was admitted for bowel rest, intravenous antibiotics, and serial examination. Tirzepatide was held. Symptoms and clinical examinations improved with non-operative management. A repeat CT scan 48 hours after presentation showed decreased pneumatosis and pneumoperitoneum with resolution of small bowel ileus (figure 2). Elemental diet was initiated and tirzepatide was discontinued. He was discharged on hospital day 3, subsequently had complete convalescence of symptoms, and returned to a normal diet after follow-up with endocrinology. A CT scan obtained approximately 6 weeks later showed resolution of pneumatosis, extraluminal gas, and ileus (figure 3). CT scan of the abdomen and pelvis (September 2, 2024): hospital day 2. Improving pneumatosis intestinalis, pneumoperitoneum. CT scan of the abdomen and pelvis (September 23, 2024). Resolution of pneumatosis intestinalis, pneumoperitoneum. Tirzepatide is a dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist. It has been demonstrated to improve glycemic control, lower HbA1c, and cause weight loss.1 The weight loss effect of GLP-1 agonists has been described in patients without diabetes mellitus, resulting in its approval and its use as a medical weight-loss agent for non-diabetic patients.2 When used for weight loss in patients without diabetes, adverse effects of GLP-1 analogs are common, but mild, consisting of nausea, vomiting, and diarrhea. More severe adverse effects have been reported, such as acute cholecystitis and gastroparesis.3 4 Careful dose titration regimens have reduced the incidence of gastrointestinal adverse events. GLP-1 and GIP agonists inhibit gastrointestinal motility and gastric emptying, possibly due to inhibition of smooth muscle contractility and the migrating myoelectric complex, especially in the intraduodenal region. Altered motility and mucosal integrity could contribute to the development of pneumatosis intestinalis; however, the exact mechanism has not been established yet. Previously, Kolli et al reported a case of tirezaptide-associated colonic pneumatosis, and non-operative management was pursued, similarly to our case, with resolution of symptoms.5 To our knowledge, there are no published cases of small bowel pneumatosis with pneumoperitoneum after initiation of tirzepatide. At this time, there are not sufficient data to support evidence-based recommendations for restarting GLP-1 receptor agonists in patients who developed pneumatosis intestinalis. Given the potential severity of pneumatosis intestinalis and the unclear pathophysiological relationship with GLP-1 receptor agonists, we had considerable concerns about reinitiating any medication from this class and elected not to restart or initiate any GLP-1 receptor agonist. The risk of recurrent pneumatosis intestinalis could outweigh the metabolic benefits of these agents, particularly given the availability of alternative obesity management strategies. This case demonstrates successful multidisciplinary management of a difficult clinical circumstance associated with an increasingly common class of medication. Paired with drug discontinuation, close observation has resulted in good outcomes. Healthcare providers should remain vigilant for gastrointestinal symptoms in patients receiving tirzepatide and other GLP-1 analogs. Early recognition of rare side effects facilitates timely evaluation and may prevent unnecessary surgical procedures. As this is a single case report, further studies are needed to establish the prevalence and underlying mechanisms of tirzepatide-induced benign pneumatosis intestinalis.